Abstract
Get full access to this article
View all access options for this article.
References
1.
Neurocrine Biosciences and
Voyager
Therapeutics
. 2019. Neurocrine Biosciences and Voyager Therapeutics form strategic development and commercialization collaboration for Parkinson's disease and Friedreich's ataxia . Available at: http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2385151 (accessed February 15 , 2019
2.Passage Bio . 2019. Passage Bio launches with $115.5 million Series A to develop AAV-delivered therapeutics to treat rare monogenic CNS diseases . Available at: https://globenewswire.com/news-release/2019/02/14/1725382/0/en/Passage-Bio-Launches-with-115-5-Million-Series-A-to-Develop-AAV-Delivered-Therapeutics-to-Treat-Rare-Monogenic-CNS-Diseases.html (accessed February 15 , 2019
3.Janssen Pharmaceuticals . 2019. Janssen enters worldwide collaboration and license agreement with MeiraGTx to develop gene therapy programs for inherited retinal diseases . Available at: https://www.janssen.com/us/sites/www_janssen_com_usa/files/janssen_enters_worldwide_collaboration_and_license_agreement_with_meiragtx_to_develop_gene_therapy_programs_for_inherited_retinal_diseases.pdf (accessed February 15 , 2019
4.uniQure . 2019 . uniQure announces updated clinical data from Phase IIb study of AMT-061 in patients with hemophilia B. Available at: https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3569276&lang=en-GB&companycode=nl-qure&v= (accessed February 15, 2019).
5.Solid Biosciences . 2019. Solid Biosciences announces preliminary SGT-001 data and intention to dose escalate in IGNITE DMD clinical trial for Duchenne Muscular Dystrophy . Available at: https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-preliminary-sgt-001-data-and-intention-to-dose-escalate-in-ignite-dmd-clinical-trial-for-duchenne-muscular-dystrophy-1 (accessed February 15 , 2019
6.U.S. Food and Drug Administration . 2019 . Evaluation of devices used with regenerative medicine advanced therapies. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585417.pdf (accessed February 15 , 2019
7.U.S. Food and Drug Administration . 2019 . Expedited programs for regenerative medicine therapies for serious conditions. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585414.pdf (accessed February 15 , 2019
8.U.S. Food and Drug Administration . 2019 . FDA advances new efforts to promote development of safe and effective regenerative medicine products. Available at: https://www.prnewswire.com/news-releases/fda-advances-new-efforts-to-promote-development-of-safe-and-effective-regenerative-medicine-products-300796610.html (accessed February 15 , 2019